French health authorities have suspended the use of Valneva’s chikungunya vaccine Ixchiq in adults aged 65 and older after ...

As safety flags hang over Valneva’s chikungunya vaccine in the U.S. and beyond, French authorities are clamping down on the shot’s use in older adults. | France’s public health agency has temporarily ...

Shares of French speciality vaccines developer Valneva (Nasdaq: VAL) were down 8.4% at 2.89 euros by early afternoon, after ...

Valneva said it has been supplying Ixchiq to help the French government respond to a major outbreak of chikungunya in La ...

France’s national public health agency is suspending immunization of adults 65 years and older with Valneva’s chikungunya ...

Shares in Valneva plunged after the company said France's health authorities suspended the use of its chikungunya vaccine, Ixchiq, for people aged 65 and older, raising concerns about the vaccine's ...

The country is considered the epicenter of the disease in the Americas, with epidemics reported over the years.

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that France’s national public health agency, the Haute Autorité de Santé (HAS), has updated its recommendat ...

Ugandan health officials will maintain Ebola surveillance and continue risk communications and patient follow-up.

The updated recommendations are pending final approval by the director of the CDC and the Department of Health and Human Services.

A panel of federal health experts recommended expanded vaccine options for several diseases, including RSV, meningitis, and chikungunya.

The Centers for Disease Control and Prevention (CDC) has recently updated its vaccine recommendations for three critical diseases: meningococcal, respiratory syncytial virus (RSV), and chikungunya.